{
    "root": "bd64aee1-c95f-4767-8d31-af93dd0ab692",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Ezetimibe and Simvastatin",
    "value": "20240414",
    "ingredients": [
        {
            "name": "EZETIMIBE",
            "code": "EOR26LQQ24"
        },
        {
            "name": "SIMVASTATIN",
            "code": "AGG2FN16EV"
        },
        {
            "name": "ASCORBIC ACID",
            "code": "PQ6CK8PD0R"
        },
        {
            "name": "BUTYLATED HYDROXYANISOLE",
            "code": "REK4960K2U"
        },
        {
            "name": "ANHYDROUS CITRIC ACID",
            "code": "XF417D3PSL"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "PROPYL GALLATE",
            "code": "8D4SNN7V92"
        }
    ],
    "indications": "ezetimibe simvastatin tablets ezetimibe simvastatin tablets combination simvastatin ezetimibe indicated : adjunct diet reduce elevated low density lipoprotein cholesterol ( ldl-c ) : adults primary hyperlipidemia . adults pediatric patients aged 10 years older heterozygous familial hypercholesterolemia ( hefh ) . adjunct ldl-c-lowering therapies reduce elevated ldl-c adults homozygous familial hypercholesterolemia ( hofh ) . simvastatin simvastatin , used component ezetimibe simvastatin tablets , indicated reduce risk total mortality reducing risk coronary heart disease death , non-fatal myocardial infarction stroke , need coronary non-coronary revascularization procedures adults established coronary heart disease , cerebrovascular disease , peripheral vascular disease , and/or diabetes , high risk coronary heart disease events .",
    "contraindications": "important information : ( 2.1 ) take ezetimibe simvastatin tablets orally daily evening without food . maximum recommended ezetimibe simvastatin tablets 10 mg/40 mg daily . ezetimibe simvastatin tablets 10 mg/80 mg daily restricted patients taking ezetimibe simvastatin tablets 10 mg/80 mg daily chronically ( e.g . , 12 months ) without evidence muscle toxicity . patients require high-intensity statin unable achieve ldl-c goal receiving ezetimibe simvastatin tablets 10 mg/40 mg daily , prescribe alternative ldl-c-lowering treatment . dose missed , take missed dose soon possible . double next dose . assess ldl-c clinically appropriate , early 2 weeks initiating ezetimibe simvastatin tablets , adjust necessary . adults : recommended range 10 mg/10 mg 10 mg/40 mg daily . ( 2.2 ) full prescribing information ezetimibe simvastatin tablets modifications due . ( 2.3 ) patients renal impairment : doses exceeding 10 mg/20 mg used caution close monitoring patients moderate severe renal impairment . ( 2.4 )",
    "warningsAndPrecautions": "ezetimibe simvastatin tablets supplied follows : strength supplied ndc tablet description 10 mg/10 mg unit bottles 30 45963-565-30 light tan , slightly speckled , round , unscored , biconvex tablet debossed 511 one side opposite side . unit bottles 90 45963-565-08 10 mg/20 mg unit bottles 30 45963-566-30 light tan , slightly speckled , round , unscored , biconvex tablet debossed 512 one side opposite side . unit bottles 90 45963-566-08 10 mg/40 mg unit bottles 30 45963-567-30 light tan , slightly speckled , round , unscored , biconvex tablet debossed 513 one side opposite side . unit bottles 90 45963-567-08 10 mg/80 mg unit bottles 30 45963-568-30 light tan , slightly speckled , capsule shaped , unscored , biconvex tablet debossed 515 one side opposite side . unit bottles 90 45963-568-08 storage store 20° 25°c ( 68° 77°f ) . [ usp controlled room temperature . ] keep container tightly closed . dispense tight , light-resistant container defined usp .",
    "adverseReactions": "ezetimibe simvastatin tablets contraindicated following conditions : concomitant strong cyp3a4 inhibitors ( select azole anti-fungals , macrolide antibiotics , anti-viral medications , nefazodone ) [ ( 7.1 ) ] . concomitant cyclosporine , danazol , danazol [ ( 7.1 ) ] . acute liver failure decompensated cirrhosis [ ( 5.3 ) ] . hypersensitivity simvastatin , ezetimibe , excipients ezetimibe simvastatin tablets . hypersensitivity , including anaphylaxis , angioedema , stevens-johnson syndrome , reported [ ( 6.2 ) ] .",
    "indications_original": "Ezetimibe and simvastatin tablets \n                  \n                  \n                     Ezetimibe and simvastatin tablets are a combination of simvastatin and ezetimibe indicated:\n                  \n                  \n                     \n                        As an adjunct to diet to reduce elevated low density lipoprotein cholesterol (LDL-C):\n                     \n                  \n                  \n                     \n                        In adults with primary hyperlipidemia.\n                     \n                     \n                        In adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH).\n                     \n                  \n                  \n                     \n                        As an adjunct to other LDL-C-lowering therapies to reduce elevated LDL-C in adults with homozygous familial hypercholesterolemia (HoFH).\n                     \n                  \n                  \n                     Simvastatin\n                  \n                  \n                     Simvastatin, when used as a component of ezetimibe and simvastatin tablets, is indicated to reduce the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease, cerebrovascular disease, peripheral vascular disease, and/or diabetes, who are at high risk of coronary heart disease events.",
    "contraindications_original": "Important Dosage and Administration Information: ( 2.1 ) Take ezetimibe and simvastatin tablets orally once daily in the evening with or without food. Maximum recommended dosage is ezetimibe and simvastatin tablets 10 mg/40 mg once daily. Ezetimibe and simvastatin tablets 10 mg/80 mg daily dosage is restricted to patients who have been taking ezetimibe and simvastatin tablets 10 mg/80 mg daily chronically (e.g., for 12 months or more) without evidence of muscle toxicity. For patients that require a high-intensity statin or are unable to achieve their LDL-C goal receiving ezetimibe and simvastatin tablets 10 mg/40 mg daily, prescribe alternative LDL-C-lowering treatment. If as dose is missed, take the missed dose as soon as possible. Do not double the next dose. Assess LDL-C when clinically appropriate, as early as 2 weeks after initiating ezetimibe and simvastatin tablets, and adjust the dosage if necessary. Adults : Recommended dosage range of 10 mg/10 mg to 10 mg/40 mg once daily. ( 2.2 ) See full prescribing information for ezetimibe and simvastatin tablets dosage modifications due to drug interactions. ( 2.3 ) Patients with Renal Impairment: Doses exceeding 10 mg/20 mg should be used with caution and close monitoring in patients with moderate to severe renal impairment. ( 2.4 )",
    "warningsAndPrecautions_original": "Ezetimibe and simvastatin tablets are supplied as follows:\n                  \n                     \n                     \n                     \n                     \n                     \n                        \n                           \n                              \n                                 Strength\n                              \n                           \n                           \n                              \n                                 How Supplied\n                              \n                           \n                           \n                              \n                                 NDC\n                              \n                           \n                           \n                              \n                                 Tablet Description\n                              \n                           \n                        \n                        \n                           \n                              10 mg/10 mg\n                           \n                           \n                              unit of use bottles of 30\n                           \n                           \n                              45963-565-30\n                           \n                           \n                              Light tan, slightly speckled, round, unscored, biconvex tablet debossed with 511 on one side and  on opposite side.\n                           \n                        \n                        \n                           \n                              unit of use bottles of 90\n                           \n                           \n                              45963-565-08\n                           \n                        \n                        \n                           \n                              10 mg/20 mg\n                           \n                           \n                              unit of use bottles of 30\n                           \n                           \n                              45963-566-30\n                           \n                           \n                              Light tan, slightly speckled, round, unscored, biconvex tablet debossed with 512 on one side and on opposite side.\n                           \n                        \n                        \n                           \n                              unit of use bottles of 90\n                           \n                           \n                              45963-566-08\n                           \n                        \n                        \n                           \n                              10 mg/40 mg\n                           \n                           \n                              unit of use bottles of 30\n                           \n                           \n                              45963-567-30\n                           \n                           \n                              Light tan, slightly speckled, round, unscored, biconvex tablet debossed with 513 on one side and on opposite side.\n                           \n                        \n                        \n                           \n                              unit of use bottles of 90\n                           \n                           \n                              45963-567-08\n                           \n                        \n                        \n                           \n                              10 mg/80 mg\n                           \n                           \n                              unit of use bottles of 30\n                           \n                           \n                              45963-568-30\n                           \n                           \n                              Light tan, slightly speckled, capsule shaped, unscored, biconvex tablet debossed with 515 on one side and on opposite side.\n                           \n                        \n                        \n                           \n                              unit of use bottles of 90\n                           \n                           \n                              45963-568-08\n                           \n                        \n                     \n                  \n                  \n                     \n                        Storage \n                     \n                  \n                  Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Keep container tightly closed. \n                  Dispense in a tight, light-resistant container as defined in the USP.",
    "adverseReactions_original": "Ezetimibe and simvastatin tablets are contraindicated in the following conditions:\n                  \n                     Concomitant use of strong CYP3A4 inhibitors (select azole anti-fungals, macrolide antibiotics, anti-viral medications, and nefazodone) [see Drug Interactions (7.1)].\n                     \n                     Concomitant use of cyclosporine, danazol, or danazol [see Drug Interactions (7.1)].\n                     \n                     Acute liver failure or decompensated cirrhosis [see Warnings and Precautions (5.3)].\n                     \n                     Hypersensitivity to simvastatin, ezetimibe, or any excipients in ezetimibe and simvastatin tablets. Hypersensitivity reactions, including anaphylaxis, angioedema, and Stevens-Johnson syndrome, have been reported [see Adverse Reactions (6.2)]."
}